Patents Examined by George C. Elliott
  • Patent number: 6165756
    Abstract: A bacterial strain of Escherichia coli BKIIM B-3996, a producer of L-threonine, containing a recombinant plasmid pVIC40 and deposited on Nov. 19, 1987 in the collection of microorganism cultures at the USSR Antiobiotics Research Institute under Reg. No. 1867.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: December 26, 2000
    Assignee: Ajinomoto Co., Inc.
    Inventors: Vladimir Georgievich Debabov, Jury Ivanovich Kozlov, Evgeny Moiseevich Khurges, Vitaly Arkadievich Livshits, Nelli Isaakovna Zhdanova, Mikhail Markovich Gusyatiner, Alexandr Konstantinovich Sokolov, Tatyana Alexandrovna Bachina, Nikolai Kazimirovich Yankovsky, Jury Dmitrievich Tsygankov, Andrei Jurievich Chistoserdov, Tatyana Grigorievna Plotnikova, Irina Clegovna Shakalis, Alla Valentinovna Belareva, Raisa Alexandrovna Arsatiants, Albert Fedorovich Sholin, Tamara Mikhailovna Pozdnyakova
  • Patent number: 6165790
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of PI3 kinase p55 gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p55 gamma. Methods of using these compounds for inhibition of PI3 kinase p55 gamma expression and for treatment of diseases associated with expression of PI3 kinase p55 gamma are provided.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Alexander H. Borchers, Donna T. Ward, Lex M. Cowsert
  • Patent number: 6165787
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: December 26, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Patent number: 6165440
    Abstract: The present invention discloses a method/system utilizing interaction of electromagnetic pulses or ultrasonic radiation with nano- and microparticles for enhancement of drug delivery in solid tumors. The particles can be attached to antibodies directed against antigens in tumor vasculature and selectively delivered to tumor blood vessel walls. Cavitation induced by ultrasonic waves or local heating of the particles by pulsed electromagnetic radiation results in perforation of tumor blood vessels, microconvection in the interstitium, and perforation of cancer cell membrane, and therefore, provides enhanced delivery of macromolecular therapeutic agents from blood into cancer cells with minimal thermal and mechanical damage to normal tissues.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: December 26, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventor: Rinat O. Esenaliev
  • Patent number: 6165786
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of Nucleolin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Nucleolin. Methods of using these compounds for modulation of Nucleolin expression and for treatment of diseases associated with expression of Nucleolin are provided.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6166182
    Abstract: Human neurotensin type 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing human neurotensin type 2 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: December 26, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Usman Shabon
  • Patent number: 6159731
    Abstract: The invention describes nucleic acids encoding the Daxx protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.
    Type: Grant
    Filed: February 12, 1998
    Date of Patent: December 12, 2000
    Assignee: Massachusetts Institute of Technology
    Inventors: Xiaolu Yang, Roya Khosravi-Far, Howard Y. Chang, David Baltimore
  • Patent number: 6159734
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Peroxisome proliferator-activated receptor gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Peroxisome proliferator-activated receptor gamma. Methods of using these compounds for modulation of Peroxisome proliferator-activated receptor gamma expression and for treatment of diseases associated with expression of Peroxisome proliferator-activated receptor gamma are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: December 12, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Robert McKay, Alexander H. Borchers, Brenda F. Baker
  • Patent number: 6159709
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: December 12, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston
  • Patent number: 6156571
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-3. Methods of using these compounds for modulation of SRC-3 expression and for treatment of diseases associated with expression of SRC-3 are provided.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: December 5, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6153599
    Abstract: Compositions and methods are provided for modulating the expression of protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. The oligonucleotides contain a methoxyethoxy (--O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting PKC expression and methods of treating conditions associated with expression of PKC using oligonucleotides of the invention are disclosed.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: November 28, 2000
    Assignees: ISIS Pharmaceuticals, Inc., Novartis AG
    Inventors: Nicholas M. Dean, Pierre Martin, Karl-Heinz Altmann
  • Patent number: 6150338
    Abstract: The present invention is directed towards gene therapy for erectile dysfunction through delivery and expression of a recombinant vector containing a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a smooth muscle cell. Also provided by the present invention is a method of inducing penile erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient number of cells of the subject to induce penile erection in the subject. The present invention also provides a recombinant vector comprising the DNA of or corresponding to at least a portion of the genome of a virus, which portion is capable of directing the expression of a DNA sequence, and DNA encoding a protein involved in the regulation of smooth muscle tone operably linked to the viral DNA and capable of being expressed as a functional gene product in the target cell.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 21, 2000
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jan Geliebter, Arnold Melman, George J. Christ, Jamil Rehman
  • Patent number: 6150092
    Abstract: The present invention relates to an antisense nucleic acid compound which has a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleotide sequence of a gene coding for a vascular endothelial growth factor and which inhibits the expression of the vascular endothelial growth factor, as well as to a therapeutic or diagnostic agent for cancers, rheumatoid arthritis, diabetes etc., comprising said antisense nucleic acid as active ingredient. Further, the present invention relates to a method of preventing the expression of the vascular endothelial growth factor, comprising use of an antisense nucleic acid compound which has a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleotide sequence of a gene coding for a vascular endothelial growth factor and which inhibits the expression of the vascular endothelial growth factor.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: November 21, 2000
    Assignee: Taogosei Company, Ltd.
    Inventors: Kiyoshi Uchida, Takayoshi Uchida, Youichi Tanaka, Yoko Matsuda, Shinichi Kondo
  • Patent number: 6146847
    Abstract: This invention provides methods and chemical agents for enhancing transient expression in eukaryotic cells. Also provided are a model system for achieving prolonged transient expression in solid tumors, a means for culturing hepatocytes without feeder cells or an extracellular matrix bonded to the substratum, a method for manipulating cellular metabolism to reduce the consumption of glucose and a means for inducing the secretion of an endogenous phosphatase activity.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: November 14, 2000
    Assignee: Genespan Corporation
    Inventors: Randal A. Goffe, Adeelia S. Goffe
  • Patent number: 6146827
    Abstract: The present invention relates, first, to the identification of novel nucleic acid molecules, termed RATH genes and RATH gene products encoded by such nucleic acid molecules, or degenerate variants thereof, that participate in the regulation, control and/or modulation of G-protein-mediated signal transduction involved in T cell activation, including, but not limited to T helper (TH) cell and TH cell subpopulation activation. Specifically, the nucleic acid molecules of the present invention include the genes corresponding to the mammalian RATH genes, including the RATH1.1 genes. Sequence analysis indicates that the RATH genes are novel genes belonging to the RGS ("regulator of G-protein signalling") gene family, a gene family which encodes gene products involved in G-protein-mediated signal transduction.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: November 14, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas Adam Levinson, Carlos J. Gimeno
  • Patent number: 6143501
    Abstract: The invention relates to new artificial tissues which comprise three-dimensional extracellular matrixes (ECM) in cross-linkable structures, cell interaction systems for inducing artificial three-dimensional tissues and which comprise genetically manipulated cells releasing immunosuppressive or cell-differentiating factors. The tissues according to the invention are suitable for producing vital transplants and for establishing models of diseases.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: November 7, 2000
    Inventors: Michael Sittinger, Olaf Schultz, Gerd R. Burmester, Thomas E. M. Haupl
  • Patent number: 6143729
    Abstract: Novel amidinium derivatives of formula (I), wherein R1 is a cholesterol derivative or an alkylamino-NR'R" grouping, and each of R2 and R3 is independently a hydrogen atom or a grouping of formula (II), wherein each of R4 and R5 is independently a hydrogen atom or a grouping of formula (III), are disclosed. The corresponding pharmaceutical compositions, which are particularly useful in gene therapy for transferring therapeutic genes into cells, are also disclosed.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: November 7, 2000
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Marie Lehn, Pierre Lehn, Jean-Pierre Vigneron
  • Patent number: 6140489
    Abstract: The invention provides a method and materials for sorting polynucleotides with oligonucleotide tags. Oligonucleotide tags of the invention are capable of hybridizing to complementary oligomeric compounds consisting of subunits having enhanced binding strength and specificity as compared to natural oligonucleotides. Such complementary oligomeric compounds are referred to herein as "tag complements." Subunits of tag complements may consist of monomers of non-natural nucleotide analogs, referred to herein as "antisense monomers" or they may comprise oligomers having lengths in the range of 3 to 6 nucleotides or analogs thereof, including antisense monomers, the oligomers being selected from a minimally cross-hybridizing set. In such a set, a duplex made up of an oligomer of the set and the complement of any other oligomer of the set contains at least two mismatches.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: October 31, 2000
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sydney Brenner
  • Patent number: 6140125
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bc1-6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bc1-6. Methods of using these compounds for modulation of bc1-6 expression and for treatment of diseases associated with expression of bc1-6 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Patent number: 6139833
    Abstract: The present invention describes a comprehensive system for gene discovery using retrovirus that have been engineered to exhibit increased accessibility to genomic DNA, or to mutate and identify the chromosomal target sequences of DNA binding proteins. The strategy employs the combination of retroviral integrase/DNA binding protein fusion constructs and gene-trapping methodologies. This novel technology provides the ability to establish proviral integration at any location within the genome. In addition, it allows for the generation of a collection of eukaryotic cells in which each cell contains a mutation in a target gene or sequence for a known DNA binding protein which also allow for rapid in vivo functional analysis. Sequence information obtained for genes identified using the described methods identify a collection of eukaryotic genes related by, or directly or indirectly regulated by, a given DNA binding protein.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: October 31, 2000
    Assignee: Lexicon Genetics Incorporated
    Inventors: Rob Burgess, Glenn Friedrich, Brian Zambrowicz, Arthur Sands